Reports Q3 revenue $45.9M, consensus $47.97M. The company reported $456.1M in cash, cash equivalents and investments, which it expects to fund the company to profitability. “The third quarter was another remarkable period of commercial and pipeline execution for Syndax (SNDX). Demand remained strong for Revuforj and Niktimvo with over $75M in combined net sales for the quarter,” said Michael Metzger, CEO. “We also furthered our leadership in menin inhibition with the addition of Revuforj to the NCCN Guidelines for R/R NPM1m AML in late September followed by FDA approval in late October. Our expansion into this second indication is underway and we are making great progress driving awareness and generating demand. Additionally, we continue to advance the development of both Revuforj and Niktimvo in the frontline setting, further unlocking their multi-billion-dollar potential.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax options imply 10.9% move in share price post-earnings
- Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025
- SNDX Upcoming Earnings Report: What to Expect?
- Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib
- Syndax Pharmaceuticals’ Revumenib Study: A Potential Game-Changer in Leukemia Treatment